Clinical trial · Interventional
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
NCT02480933CI-TRIAL-00030536SISYPHUSunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to define silent breast cancer prevalence in both sexes and will be held by biopsies performed in imaging suspicious areas of the breast (ecography and mammography) in cadavers without known breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Female Breast Cancer | — | UNRESOLVED | — |
| Male Breast Cancer | Male Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bilateral mastectomy | Procedure | — | UNRESOLVED |
| Biopsy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- female cadavers
- description
- female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
- interventionNames
- Procedure: Bilateral mastectomy
- Other: Biopsy
- type
- EXPERIMENTAL
- label
- Male cadavers
- description
- male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
- interventionNames
- Procedure: Bilateral mastectomy
- Other: Biopsy
Primary outcomes (1)
- measure
- Silent breast cancer prevalence
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Female and male cadavers above 40 years Exclusion Criteria: * Known breast cancer * Breast tissue accidental damage
References
Publications (0)
Data not yet available
No reference posted for this study.